13-32329548-C-T

Variant summary

Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_000059.4(BRCA2):​c.681+56C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.19 in 1,307,266 control chromosomes in the GnomAD database, including 24,994 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★★).

Frequency

Genomes: 𝑓 0.21 ( 3387 hom., cov: 32)
Exomes 𝑓: 0.19 ( 21607 hom. )

Consequence

BRCA2
NM_000059.4 intron

Scores

2

Clinical Significance

Benign reviewed by expert panel U:1B:14

Conservation

PhyloP100: -0.265
Variant links:
Genes affected
BRCA2 (HGNC:1101): (BRCA2 DNA repair associated) Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The largest exon in both genes is exon 11, which harbors the most important and frequent mutations in breast cancer patients. The BRCA2 gene was found on chromosome 13q12.3 in human. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq, May 2020]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -20 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.8).
BP6
Variant 13-32329548-C-T is Benign according to our data. Variant chr13-32329548-C-T is described in ClinVar as [Benign]. Clinvar id is 126192.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr13-32329548-C-T is described in Lovd as [Likely_benign]. Variant chr13-32329548-C-T is described in Lovd as [Benign].
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.246 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
BRCA2NM_000059.4 linkc.681+56C>T intron_variant Intron 8 of 26 ENST00000380152.8 NP_000050.3 P51587

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
BRCA2ENST00000380152.8 linkc.681+56C>T intron_variant Intron 8 of 26 5 NM_000059.4 ENSP00000369497.3 P51587
BRCA2ENST00000530893.7 linkc.312+56C>T intron_variant Intron 8 of 26 1 ENSP00000499438.2 A0A590UJI7
BRCA2ENST00000614259.2 linkn.681+56C>T intron_variant Intron 7 of 25 2 ENSP00000506251.1 A0A7P0TAP7

Frequencies

GnomAD3 genomes
AF:
0.205
AC:
31123
AN:
151760
Hom.:
3378
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.249
Gnomad AMI
AF:
0.222
Gnomad AMR
AF:
0.204
Gnomad ASJ
AF:
0.165
Gnomad EAS
AF:
0.0824
Gnomad SAS
AF:
0.126
Gnomad FIN
AF:
0.254
Gnomad MID
AF:
0.142
Gnomad NFE
AF:
0.188
Gnomad OTH
AF:
0.191
GnomAD4 exome
AF:
0.188
AC:
217330
AN:
1155390
Hom.:
21607
AF XY:
0.185
AC XY:
108379
AN XY:
584296
show subpopulations
Gnomad4 AFR exome
AF:
0.244
Gnomad4 AMR exome
AF:
0.227
Gnomad4 ASJ exome
AF:
0.169
Gnomad4 EAS exome
AF:
0.0576
Gnomad4 SAS exome
AF:
0.134
Gnomad4 FIN exome
AF:
0.256
Gnomad4 NFE exome
AF:
0.192
Gnomad4 OTH exome
AF:
0.191
GnomAD4 genome
AF:
0.205
AC:
31170
AN:
151876
Hom.:
3387
Cov.:
32
AF XY:
0.204
AC XY:
15168
AN XY:
74230
show subpopulations
Gnomad4 AFR
AF:
0.250
Gnomad4 AMR
AF:
0.204
Gnomad4 ASJ
AF:
0.165
Gnomad4 EAS
AF:
0.0830
Gnomad4 SAS
AF:
0.127
Gnomad4 FIN
AF:
0.254
Gnomad4 NFE
AF:
0.188
Gnomad4 OTH
AF:
0.189
Alfa
AF:
0.189
Hom.:
3485
Bravo
AF:
0.206
Asia WGS
AF:
0.141
AC:
489
AN:
3464

ClinVar

Significance: Benign
Submissions summary: Uncertain:1Benign:14
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Breast-ovarian cancer, familial, susceptibility to, 2 Uncertain:1Benign:4
Oct 09, 2014
Genome Diagnostics Laboratory, University Medical Center Utrecht
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Apr 12, 1999
Breast Cancer Information Core (BIC) (BRCA2)
Significance: Uncertain significance
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Jan 12, 2015
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA)
Significance: Benign
Review Status: reviewed by expert panel
Collection Method: curation

Class 1 not pathogenic based on frequency >1% in an outbred sampleset. Frequency 0.07343 (Asian), 0.313 (African), 0.2018 (European), derived from 1000 genomes (2012-04-30). -

Jul 07, 2023
KCCC/NGS Laboratory, Kuwait Cancer Control Center
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

-
GreenArray Genomic Research & Solutions of Accurate Diagnostic Private Limited
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

not specified Benign:4
-
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Nov 01, 2017
GeneKor MSA
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Apr 20, 2017
Department of Pathology and Molecular Medicine, Queen's University
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

-
Clinical Genetics Laboratory, Department of Pathology, Netherlands Cancer Institute
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Hereditary cancer-predisposing syndrome Benign:2
Nov 19, 2014
Ambry Genetics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Dec 09, 2014
Color Diagnostics, LLC DBA Color Health
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Hereditary breast ovarian cancer syndrome Benign:2
Jan 06, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Apr 19, 2022
National Health Laboratory Service, Universitas Academic Hospital and University of the Free State
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

not provided Benign:1
-
Breakthrough Genomics, Breakthrough Genomics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: not provided

- -

Familial cancer of breast Benign:1
Feb 01, 2025
KCCC/NGS Laboratory, Kuwait Cancer Control Center
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.80
CADD
Benign
7.0
DANN
Benign
0.63

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs2126042; hg19: chr13-32903685; COSMIC: COSV66457755; API